Physician profile
Tom Yang
NPI 1548346695
$14,896.60
in general payments reported to CMS, 2019-2025
23 companies · $3,478 in 2025
The $3,478 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,343 · 2020: $891 · 2021: $2,000 · 2022: $2,171 · 2023: $2,229 · 2024: $2,785 · 2025: $3,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,492.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,132.96 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $4,353.70 | 2019-2025 | Velphoro, Velphoro |
| Ardelyx, INC. | $1,083.96 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Amgen INC. | $515.16 | 2024-2025 | Krystexxa, Tavneos |
| Calliditas Therapeutics US INC. | $499.71 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $466.14 | 2019-2025 | Vafseo |
| Novo Nordisk INC | $401.46 | 2023-2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $383.45 | 2020-2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $351.19 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $286.90 | 2022-2025 | |
| Horizon Therapeutics Plc | $283.71 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $199.37 | 2025 | Jardiance, Mounjaro, Zepbound |
| Travere Therapeutics, INC. | $196.33 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $196.19 | 2019-2025 | Jynarque, Voyxact |
| Baxter Healthcare | $124.74 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $104.95 | 2022-2023 | Veltassa |
| Daiichi Sankyo INC. | $104.48 | 2019-2024 | Injectafer |
| Amicus Therapeutics, INC. | $69.82 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $39.81 | 2019-2024 | Xarelto |
| Scpharmaceuticals INC. | $36.18 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $26.70 | 2023 | Arcalyst |
| Aurinia Pharma U.S., INC. | $24.70 | 2021 | |
| Glaxosmithkline, LLC. | $14.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tom Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.